CHO Business Summary

CHO Pharma (6586.TWO), also known as GlycoNova, operates a "double-engine" business model centered on its proprietary CHOptimax™ glycoengineering platform, which generates revenue through technology licensing, milestone payments, and co-development royalties. The company specializes in the precise modification of Fc-glycans to create homogeneous antibody biobetters, site-specific antibody-drug conjugates (ADCs), and carbohydrate-based vaccines. Its primary business segments include therapeutic platforms for infectious diseases and oncology, with a pipeline featuring CHO-H01 for lymphoma, the SSEA-4 targeting antibody CHO-A04, and the bivalent vaccine CHO-V08. Within the competitive landscape, CHO Pharma distinguishes itself as a specialized glycan technology provider, competing directly with OBI Pharma, GlycoMimetics, and Halozyme Therapeutics by offering a scalable, one-pot enzymatic process that significantly reduces production complexity compared to traditional heterogeneous glycosylation methods. The leadership team is anchored by Chairman Dr. Chao-Long Chen, a world-renowned liver transplant pioneer and former superintendent of Kaohsiung Chang Gung Memorial Hospital, and President/CEO Dr. Chung-Yi Wu, a former Research Professor at Academia Sinica with over 20 years of glycoscience expertise. The company was founded in 2013 as a spin-off from Academia Sinica, with its scientific foundation established by Science Advisory Board Chairman Dr. Chi-Huey Wong, the former President of Academia Sinica and a Wolf Prize laureate. CHO Pharma maintains a robust institutional backing, with Academia Sinica holding a 33.2% stake, alongside significant investments from Diamond Biofund, Fubon Financial (led by Richard Tsai), and Lian Ding Capital, a consortium including tech giants United Microelectronics (UMC) and WIN Semiconductors.